1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited

SUNPHARMA.BO
Sun Pharmaceutical Industries LimitedIN flagBombay Stock Exchange
1,887.95
INR
-15.05
- -
4.53TMarket Cap
Sun Pharmaceutical Industries Limited
SUNPHARMA.BO
(Bombay Stock Exchange)

Recent

price

1,887.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
27.65
38.63
54.25
77.27
113.29
114.27
124.8
108.64
119.56
134.73
138.51
159.68
180.38
199.05
217.14
- -
222.54
Revenue per Share
8.77
12.83
14.4
15.17
18.88
18.89
28.98
8.73
11.11
15.69
12.1
13.6
35.32
39.91
45.6
- -
43.3
Basic EPS, GAAP
8.99
7.35
12.12
14.74
13.61
13.64
14.1
8.11
-4.24
20.89
20.84
31.12
11.98
41.4
49.83
- -
- -
Free Cash Flow per Basic Share
1.37
1.7
2.12
2.5
1.29
3
1
3.33
2
5.75
6.5
8.97
10.5
12.08
15.08
- -
- -
Dividend per Share
23.27
32.72
43.94
57.86
90.99
105.57
128.51
134.28
139.91
148.21
153.53
157.44
182.76
210.04
242.42
- -
- -
Book Value per Share
44.76
58.23
68.26
82.69
100.86
115.55
124.89
131.18
135.09
151.22
156.42
159.94
173.51
207.66
227.5
- -
- -
Tangible Book Value per Share
2,071
2,071
2,071
2,071
2,405
2,406
2,403
2,399
2,399
2,399
2,399
2,406
2,399
2,399
2,397
- -
2,395
Basic Weighted Avg Shares
57,278
80,014
112,359
160,044
272,451
274,981
299,944
260,650
286,863
323,252
332,331
384,264
432,789
477,584
520,412
582,201
533,028
Sales/Revenue/Turnover
30.4
37.13
40.99
42.14
25.05
27.26
28.29
15.61
16.45
15.25
19.3
21.08
21.44
21.92
24.18
23.35
24.16
Operating Margin (%)
2,048
2,912
3,362
4,092
11,947
10,375
12,648
14,998
17,532
20,528
20,800
21,437
25,304
25,568
25,754
29,378
26,208
Depreciation Expense
18,161
26,567
29,831
31,415
45,394
45,457
69,644
20,957
26,654
37,649
29,038
32,727
84,736
95,764
109,290
114,794
103,720
Net Income, GAAP
6.31
9.33
19.57
15.33
14.29
13.91
13.39
26.19
15.77
16.42
18.39
24
9.01
12.98
20.16
23.51
22.89
Effective Tax Rate (%)
31.71
33.2
26.55
19.63
16.66
16.53
23.22
8.04
9.29
11.65
8.74
8.52
19.58
20.05
21
19.72
19.46
Profit Margin (%)
58,622
76,749
86,618
126,968
135,488
167,973
150,666
117,716
137,296
159,477
142,964
178,144
199,763
264,906
344,303
412,692
- -
Working Capital
1,573
1,554
1,153
487
13,598
31,103
14,361
17,721
15,226
20,289
8,981
4,817
5,599
3,036
3,583
3,929
- -
LT Debt
103,305
133,972
166,248
204,461
308,926
370,677
404,305
421,983
447,226
491,247
494,798
510,661
593,155
671,259
724,860
838,797
- -
Total Equity
17.23
22.02
24.22
28.65
18.48
15.02
15.34
5.86
7.39
7.32
9.44
11.66
14.24
13.28
13.69
12.46
- -
Return on Invested Capital (%)
34.56
32
26.23
17.63
15.39
10.31
15.44
4.36
5.46
7.57
7.98
7.57
17.84
17.54
18.8
17.31
275.43
Return on Capital (%)
41.54
45.82
37.58
29.8
26.81
19.23
24.74
6.64
8.1
10.89
8.02
8.76
20.73
20.32
20.15
17.98
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
20,039
- -
LT Borrowings
- -
25
- -
LT Finance Leases
- -
3,557
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
2,399
- -
Market Capitalization
4,520,527
4,158,632
4,016,199

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
526,245
- -
Cash, Cash Equivalents & STI
- -
263,176
- -
Accounts Receivable, Net
- -
130,461
- -
Inventories
- -
102,433
- -
Total Current Liabilities
- -
181,942
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
20,039
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.62%
11.25%
15.72%
Free Cash Flow
-55.72%
45.56%
-26.24%
Net Income, GAAP
23.27%
40.76%
5.04%
Sales/Revenue/Turnover
8.1%
11.89%
11.87%
Total Cash Common Dividend
43.01%
20.74%
8.85%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
117,852
120,031
121,569
118,133
477,584
2025
125,245
132,642
134,369
128,156
520,412
2026
137,861
154,691
145,598
- -
582,201

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8.4
9.9
10.5
- -
39.91
2025
11.8
12.7
12.1
9
45.6
2026
9.5
14
11.3
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
12.08
2025
- -
- -
- -
- -
15.08
2026
- -
- -
- -
- -
- -
Similar Companies
Bio Essence Corporation (BIOE)
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
Captiva Verde Wellness Corp. (CPIVF)
Suven Life Sciences Limited (SUVEN.BO)
West Island Brands Inc. (WIBFF)
Walvax Biotechnology Co., Ltd. (300142.SZ)
Business
Sun Pharmaceutical Industries Limited (SUNPHARMA.BO) is India's largest pharmaceutical company and a leading global specialty generic manufacturer that develops, manufactures and markets a broad portfolio of branded generics, generics, specialty and complex products, over-the-counter (OTC) medications, antiretrovirals (ARVs) and active pharmaceutical ingredients (APIs) including intermediates; its offerings span diverse dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, liquids, nasal sprays, lyophilized injections and controlled-release formulations across therapeutic areas including neuro-psychiatry, cardiology, anti-infectives, diabetology, gastroenterology, oncology, dermatology, ophthalmology, nephrology, urology, respiratory, orthopaedics and nutritionals, with flagship OTC brands like Volini, Revital, Faringosept, Coldact and Chericof; the company operates 41 manufacturing facilities and supplies products to over 100 countries, maintaining strong positions in the US (No. 2 in generic dermatology), emerging markets including Brazil, Mexico, South Africa and key developed markets like Canada, Australia, Western Europe and Japan. Founded in 1983 by Dilip Shanghvi and headquartered in Mumbai, India, Sun Pharma generates global revenues of US$6.2 billion with over 43,000 employees and invests 6-8% annually in R&D through a team of more than 2,900 personnel focused on complex generics and differentiated innovations like liposomal drugs. In recent developments, the company acquired US-based Checkpoint Therapeutics for $355 million in March 2025 to expand its oncology and immunotherapy pipeline with the FDA-approved PD-L1 inhibitor Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma, bolstering its onco-dermatology portfolio; its US subsidiary Taro Pharma completed the acquisition of Canada's Antibe Therapeutics by March 2025 to enhance presence in novel therapeutics; and Sun Pharma finalized full ownership of Taro Pharma in 2025, consolidating its global dermatology capabilities.